Profile data is unavailable for this security.
About the company
Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
- Revenue in EUR (TTM)13.61m
- Net income in EUR-311.07m
- Incorporated2011
- Employees84.00
- LocationInventiva SA50 rue de Dijon, DaixDAIX 21121FranceFRA
- Phone+33 380447500
- Websitehttps://inventivapharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transgene SA | 7.24m | -36.78m | 233.06m | 147.00 | -- | -- | -- | 32.19 | -0.1456 | -0.1456 | 0.0618 | -0.0272 | 0.1578 | -- | 8.72 | 43,872.73 | -80.19 | -33.32 | -186.71 | -40.55 | -- | -- | -508.10 | -251.37 | -- | -17.28 | 1.13 | -- | -20.34 | -14.48 | -52.15 | -- | 12.68 | -- |
| Cellectis SA | 69.56m | -29.79m | 238.31m | 224.00 | -- | 2.82 | -- | 3.43 | -0.297 | -0.297 | 0.6916 | 1.17 | 0.2234 | -- | 8.58 | 310,550.20 | -9.57 | -21.50 | -16.65 | -29.24 | -- | -32.79 | -42.82 | -220.86 | -- | -3.13 | 0.5013 | -- | 435.37 | 16.44 | 66.41 | -- | -21.58 | -- |
| Eurobio Scientific SA | 162.09m | 2.36m | 246.49m | 380.00 | 102.51 | 1.33 | 13.83 | 1.52 | 0.2346 | 0.2346 | 15.76 | 18.03 | 0.5651 | 1.62 | 5.21 | 497,196.30 | 0.8231 | 14.00 | 1.02 | 17.37 | 23.69 | 51.40 | 1.46 | 20.70 | 1.25 | 1.72 | 0.0845 | 0.00 | 18.89 | 21.21 | -17.31 | 4.86 | 15.38 | -- |
| Genfit SA | 45.41m | -38.76m | 356.76m | 188.00 | -- | 6.79 | -- | 7.86 | -0.7737 | -0.7737 | 0.9083 | 1.05 | 0.2207 | 519.75 | 0.9236 | 252,277.80 | -18.84 | -7.73 | -23.25 | -9.79 | 95.42 | 95.68 | -85.35 | -37.15 | 3.74 | -10.87 | 0.1223 | -- | 85.82 | 11.61 | 105.22 | -- | -13.57 | -- |
| Valneva SE | 179.91m | -102.16m | 747.06m | 700.00 | -- | 4.95 | -- | 4.15 | -0.5807 | -0.5807 | 1.08 | 0.8762 | 0.3729 | 1.61 | 7.13 | 258,867.60 | -21.18 | -14.46 | -28.97 | -23.62 | 45.36 | 34.12 | -56.78 | -34.54 | 1.36 | -3.61 | 0.5655 | -- | 10.32 | 6.09 | 87.93 | -- | 8.60 | -- |
| Nanobiotix SA | -14.04m | -51.64m | 1.01bn | 103.00 | -- | -- | -- | -- | -1.09 | -1.09 | -0.2962 | -1.43 | -0.213 | -- | -- | -130,037.00 | -78.34 | -54.39 | -839.67 | -90.60 | -- | -- | -- | -1,326.20 | -- | -7.32 | -- | -- | -138.62 | -- | -71.62 | -- | -10.10 | -- |
| Inventiva SA | 13.61m | -311.07m | 1.09bn | 84.00 | -- | -- | -- | 80.22 | -3.62 | -3.62 | 0.1543 | -0.064 | 0.1247 | -- | 2.35 | 124,871.60 | -284.55 | -80.43 | -555.93 | -122.98 | -- | -- | -2,282.71 | -989.96 | -- | -0.5041 | 1.18 | -- | -47.37 | 5.62 | -66.82 | -- | 19.61 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Invus Public Equities Advisors LLCas of 13 Nov 2025 | 15.95m | 8.31% |
| Deep Track Capital LPas of 23 Jan 2026 | 12.08m | 6.29% |
| BVF Partners LPas of 17 Nov 2025 | 8.88m | 4.63% |
| Perceptive Advisors LLCas of 30 Sep 2025 | 6.95m | 3.62% |
| Great Point Partners LLCas of 30 Sep 2025 | 5.30m | 2.76% |
| Qatar Investment Authority (Investment Management)as of 24 Jul 2025 | 5.16m | 2.69% |
| Polar Capital LLPas of 31 Dec 2025 | 3.51m | 1.83% |
| CPR Asset Management SAas of 30 Sep 2025 | 1.01m | 0.53% |
| Alphajet Fair Investors SASas of 10 Feb 2026 | 100.00k | 0.05% |
| Financi�re de l'�chiquier SAas of 31 Oct 2025 | 36.75k | 0.02% |
